New Delhi: The emergence of a new COVID-19 variant, PJ.2.1, has drawn the attention of scientists, who are investigating its transmissibility, genetic characteristics and ability to enter human cells. First identified in Ontario, Canada, in May 2026, the variant has subsequently been detected in parts of North America, Europe, Asia and Oceania.
Researchers are examining whether genetic changes in PJ.2.1 could make it more efficient at entering human cells and whether these mutations could affect immunity developed through existing COVID-19 vaccines. However, early research has not established that the variant is more resistant to vaccine-induced antibodies than other circulating variants.
Changes in spike protein under investigation
A scientific study published in October 2026 examined the structure of PJ.2.1 and the changes in its spike protein. The findings suggested that the variant might have an increased ability to interact with the S2-related entry mechanism involved in coronavirus infection of human cells.
The spike protein, which forms projections on the virus’s outer surface, plays a key role in its interaction with human cells and the process of entering them. Genetic changes in this protein can influence how the virus interacts with cellular receptors and gains access to cells.
Scientists are therefore examining the mutations in PJ.2.1 to determine whether they provide any biological advantage to the virus.
What is a saltation variant?
Researchers have classified PJ.2.1 as a saltation variant. The term describes a virus that appears to acquire a relatively large number of genetic changes over a short evolutionary period, rather than accumulating mutations gradually.
According to the study, PJ.2.1 is believed to have originated from MC.10.1.7, a lineage linked to the JN.1 family, which was circulating until May 2025.
Understanding this genetic relationship could help researchers trace the variant’s evolution and identify the changes responsible for its emergence.
Early findings offer some reassurance on vaccine effectiveness
The possible impact of PJ.2.1 on vaccine-induced immunity remains an important area of investigation. Initial findings have not provided convincing evidence that antibodies generated through existing COVID-19 vaccines are substantially less effective against this variant than against other variants.
This is an encouraging early indication, although researchers caution against drawing definitive conclusions. Further studies are required to assess how effectively existing immunity protects against infection and whether the variant has any advantage in evading the body’s immune response.
Scientists are also examining whether PJ.2.1 has any association with changes in disease severity.
Flu-like symptoms make diagnosis difficult
Identifying COVID-19 infections remains challenging because several symptoms overlap with influenza and other respiratory illnesses.
The World Health Organization has noted that symptoms such as fever and cough can occur in different respiratory infections. Consequently, symptoms alone cannot reliably establish whether a person has COVID-19. Appropriate testing may be required for confirmation.
Continued monitoring and research
Scientists are continuing to monitor the geographical spread and biological characteristics of PJ.2.1. Its emergence has renewed attention on the need for genomic surveillance and regular assessment of changes in circulating coronavirus lineages.
At present, there is no conclusive evidence that PJ.2.1 is more capable than other variants of escaping vaccine-induced immunity or causing severe illness. Its actual public health impact will become clearer as further laboratory studies, clinical observations and epidemiological data become available.
https://www.youtube.com/watch?si=RtToJsBhYBatUrym&v=mOuYNSdhjHA&feature=youtu.be
